Uncategorized

KHN’s ‘What the Health?’: Our 200th Episode!

Posted on

The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.

Uncategorized

Labelling update regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) beyond 20 weeks of pregnancy and risk of kidney damage to unborn babies

Posted on

Health Canada has completed a safety review confirming that the use of non-steroid anti-inflammatory drugs (NSAIDs)—such as acetylsalicylic acid (aspirin), ibuprofen, naproxen, diclofenac and celecoxib —starting from approximately 20 weeks of pregnancy or later, may cause rare but serious kidney problems in an unborn baby. This can lead to low levels of amniotic fluid and possible complications, such as impaired lung maturation and loss of joint movement (limb contractures) in the newborn baby.